Will These Numbers from Charles River Laboratories International Be Good Enough for You?
Charles River Laboratories International (NYS: CRL) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Charles River Laboratories International's revenues will expand 0.4% and EPS will expand 8.8%.
The average estimate for revenue is $278.8 million. On the bottom line, the average EPS estimate is $0.62.
Last quarter, Charles River Laboratories International logged revenue of $284.7 million. GAAP reported sales were 1.2% lower than the prior-year quarter's $288.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.75. GAAP EPS of $0.63 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.4%, 50 basis points worse than the prior-year quarter. Operating margin was 17.3%, 120 basis points worse than the prior-year quarter. Net margin was 10.7%, 50 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.14 billion. The average EPS estimate is $2.72.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $39.35.
- Add Charles River Laboratories International to My Watchlist.
The article Will These Numbers from Charles River Laboratories International Be Good Enough for You? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.